MedTrace Logo

Use of Virtual Reality in the Treatment of Flying Phobia

NCT01442805 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-15

No results posted yet for this study

Summary

The project aims to explore the potential of Virtual Reality Exposure Therapy (VRET) for the treatment of the fear of driving, the fear of flying and the fear of public speaking.

The study is a randomized controlled trial (RCT) designed to compare the efficiency of cognitive behavioural therapy with exposures in imagination to behavioural therapy with exposures in virtual reality. Anxiety levels are measured using specific questionnaires, SUD ratings and physiological measures (heart rate, skin conductance, skin temperature, breathing frequency, heart rate variability).

Hypothesis: Treatments with exposures in virtual reality are more efficient than treatments with exposures in imagination.

Conditions

  • Flying Phobia

Interventions

BEHAVIORAL

Virtual Reality Exposure Therapy

Participants are exposed to the feared situation (flying) through the virtual reality technology

BEHAVIORAL

Exposure Therapy through Imagination

Participants are exposed to the feared situation (flying) through exposure technique of imagination.

Sponsors & Collaborators

  • Centre Hospitalier du Luxembourg

    collaborator OTHER

  • Luxembourg Institute of Health

    lead OTHER_GOV

Principal Investigators

  • Charles Pull, Prof.Dr. · Centre de Recherche Public de la Santé

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-09-30
Completion
2012-03-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442805 on ClinicalTrials.gov